HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?
Assessment of homologous recombination deficiency (HRD) status is now essential for ovarian cancer patient management. The aim of our study was to analyze the influence of ethnic variations, tumor purity, and neoadjuvant chemotherapy (CT) on the determination of HRD scores as well as to evaluate fea...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/13/10497 |
| _version_ | 1797591613365551104 |
|---|---|
| author | Tatiana Kekeeva Yulia Andreeva Alexander Tanas Alexey Kalinkin Svetlana Khokhlova Tatiana Tikhomirova Alexandra Tyulyandina Anatoly Popov Maria Kuzmenko Mikhail Volkonsky Natalia Chernorubashkina Valeria Saevets Vadim Dmitriev Valentina Nechushkina Olga Vedrova Sergei Andreev Sergey Kutsev Vladimir Strelnikov |
| author_facet | Tatiana Kekeeva Yulia Andreeva Alexander Tanas Alexey Kalinkin Svetlana Khokhlova Tatiana Tikhomirova Alexandra Tyulyandina Anatoly Popov Maria Kuzmenko Mikhail Volkonsky Natalia Chernorubashkina Valeria Saevets Vadim Dmitriev Valentina Nechushkina Olga Vedrova Sergei Andreev Sergey Kutsev Vladimir Strelnikov |
| author_sort | Tatiana Kekeeva |
| collection | DOAJ |
| description | Assessment of homologous recombination deficiency (HRD) status is now essential for ovarian cancer patient management. The aim of our study was to analyze the influence of ethnic variations, tumor purity, and neoadjuvant chemotherapy (CT) on the determination of HRD scores as well as to evaluate feasibility of HRD testing with the Amoy HRD Focus Assay in routine clinical practice. The HRD status, including the <i>BRCA</i> status and genomic scar score (GSS), was analyzed in 452 ovarian cancer specimens. The successful rate of HRD testing was 86% (388/452). The <i>BRCA</i> mutational rate was 29% (114/388); 252 samples (65%) were classified as HRD-positive. Our data demonstrate the feasibility of internal HRD testing by the AmoyDx HRD Focus Panel for high-grade serous ovarian cancer (HGSOC), showing results similar to other methods. The HRD rate in the Russian population is very similar to those of other European populations, as is the <i>BRCA</i> mutation frequency. The most substantial contribution to HRD level diversity is testing criteria depending on intrahospital arrangements. The analysis shows that biallelic <i>BRCA</i> alterations had higher GSS compared with those with monoallelic inactivation, consistent with positive HRD status. The study indicates that grades 1–2 of the pathological response caused by chemotherapy affect HRD scores and suggests controlling for tumor purity of 40% or more as a critical factor for GSS measurement. |
| first_indexed | 2024-03-11T01:39:50Z |
| format | Article |
| id | doaj.art-3682af6d9f4047ae80003204e2316d3c |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T01:39:50Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-3682af6d9f4047ae80003204e2316d3c2023-11-18T16:39:07ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-06-0124131049710.3390/ijms241310497HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?Tatiana Kekeeva0Yulia Andreeva1Alexander Tanas2Alexey Kalinkin3Svetlana Khokhlova4Tatiana Tikhomirova5Alexandra Tyulyandina6Anatoly Popov7Maria Kuzmenko8Mikhail Volkonsky9Natalia Chernorubashkina10Valeria Saevets11Vadim Dmitriev12Valentina Nechushkina13Olga Vedrova14Sergei Andreev15Sergey Kutsev16Vladimir Strelnikov17Laboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechie St., 1, 115522 Moscow, RussiaDepartment of Pathology, Russian Medical Academy of Continuing Professional Education, 125993 Moscow, RussiaLaboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechie St., 1, 115522 Moscow, RussiaLaboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechie St., 1, 115522 Moscow, RussiaOncological Department of Medical Treatment, National Medical Research Center for Obstetrics, Gynecology and Perinatology Named after V. I. Kulakov, 117997 Moscow, RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, 115478 Moscow, RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, 115478 Moscow, RussiaNational Medical Research Center of Surgery Named after A. Vishnevsky, Department of Antitumor Drug Therapy, 117997 Moscow, RussiaDepartment of Oncology, Radiology and Radiotherapy, Tyumen State Medical University, 625023 Tyumen, RussiaDay Hospital No. 1, Moscow Municipal Oncological Hospital No. 62, 143423 Moscow, RussiaDepartment of Surgical Methods of Treatment No. 9, State Budgetary Healthcare Institution Regional Oncological Dispensary, 664035 Irkutsk, RussiaGynecological Oncology Department, Chelyabinsk Regional Clinical Centre for Oncology and Nuclear Medicine, 454087 Chelyabinsk, RussiaDepartment of Theoretical Surgery, Belgorod National Research University, 308015 Belgorod, RussiaDepartment of Oncology, Diagnostic Radiology and Radiotherapy, Privolzhsky Research Medical University, 603005 Nizhniy Novgorod, RussiaAstrazeneca Pharmaceuticals LLC, 123112 Moscow, RussiaAstrazeneca Pharmaceuticals LLC, 123112 Moscow, RussiaLaboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechie St., 1, 115522 Moscow, RussiaLaboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechie St., 1, 115522 Moscow, RussiaAssessment of homologous recombination deficiency (HRD) status is now essential for ovarian cancer patient management. The aim of our study was to analyze the influence of ethnic variations, tumor purity, and neoadjuvant chemotherapy (CT) on the determination of HRD scores as well as to evaluate feasibility of HRD testing with the Amoy HRD Focus Assay in routine clinical practice. The HRD status, including the <i>BRCA</i> status and genomic scar score (GSS), was analyzed in 452 ovarian cancer specimens. The successful rate of HRD testing was 86% (388/452). The <i>BRCA</i> mutational rate was 29% (114/388); 252 samples (65%) were classified as HRD-positive. Our data demonstrate the feasibility of internal HRD testing by the AmoyDx HRD Focus Panel for high-grade serous ovarian cancer (HGSOC), showing results similar to other methods. The HRD rate in the Russian population is very similar to those of other European populations, as is the <i>BRCA</i> mutation frequency. The most substantial contribution to HRD level diversity is testing criteria depending on intrahospital arrangements. The analysis shows that biallelic <i>BRCA</i> alterations had higher GSS compared with those with monoallelic inactivation, consistent with positive HRD status. The study indicates that grades 1–2 of the pathological response caused by chemotherapy affect HRD scores and suggests controlling for tumor purity of 40% or more as a critical factor for GSS measurement.https://www.mdpi.com/1422-0067/24/13/10497homologous recombination deficiency<i>BRCA</i> mutationgenomic instability scoretumor puritypathological response |
| spellingShingle | Tatiana Kekeeva Yulia Andreeva Alexander Tanas Alexey Kalinkin Svetlana Khokhlova Tatiana Tikhomirova Alexandra Tyulyandina Anatoly Popov Maria Kuzmenko Mikhail Volkonsky Natalia Chernorubashkina Valeria Saevets Vadim Dmitriev Valentina Nechushkina Olga Vedrova Sergei Andreev Sergey Kutsev Vladimir Strelnikov HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With? International Journal of Molecular Sciences homologous recombination deficiency <i>BRCA</i> mutation genomic instability score tumor purity pathological response |
| title | HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With? |
| title_full | HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With? |
| title_fullStr | HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With? |
| title_full_unstemmed | HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With? |
| title_short | HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With? |
| title_sort | hrd testing of ovarian cancer in routine practice what are we dealing with |
| topic | homologous recombination deficiency <i>BRCA</i> mutation genomic instability score tumor purity pathological response |
| url | https://www.mdpi.com/1422-0067/24/13/10497 |
| work_keys_str_mv | AT tatianakekeeva hrdtestingofovariancancerinroutinepracticewhatarewedealingwith AT yuliaandreeva hrdtestingofovariancancerinroutinepracticewhatarewedealingwith AT alexandertanas hrdtestingofovariancancerinroutinepracticewhatarewedealingwith AT alexeykalinkin hrdtestingofovariancancerinroutinepracticewhatarewedealingwith AT svetlanakhokhlova hrdtestingofovariancancerinroutinepracticewhatarewedealingwith AT tatianatikhomirova hrdtestingofovariancancerinroutinepracticewhatarewedealingwith AT alexandratyulyandina hrdtestingofovariancancerinroutinepracticewhatarewedealingwith AT anatolypopov hrdtestingofovariancancerinroutinepracticewhatarewedealingwith AT mariakuzmenko hrdtestingofovariancancerinroutinepracticewhatarewedealingwith AT mikhailvolkonsky hrdtestingofovariancancerinroutinepracticewhatarewedealingwith AT nataliachernorubashkina hrdtestingofovariancancerinroutinepracticewhatarewedealingwith AT valeriasaevets hrdtestingofovariancancerinroutinepracticewhatarewedealingwith AT vadimdmitriev hrdtestingofovariancancerinroutinepracticewhatarewedealingwith AT valentinanechushkina hrdtestingofovariancancerinroutinepracticewhatarewedealingwith AT olgavedrova hrdtestingofovariancancerinroutinepracticewhatarewedealingwith AT sergeiandreev hrdtestingofovariancancerinroutinepracticewhatarewedealingwith AT sergeykutsev hrdtestingofovariancancerinroutinepracticewhatarewedealingwith AT vladimirstrelnikov hrdtestingofovariancancerinroutinepracticewhatarewedealingwith |